- •Estimates on the distribution of patients with multiple myeloma by line of therapy are scarce and become outdated quickly as new treatments become available.
- •A mathematical model was developed to calculate the number of patients with MM by line of therapy and prior treatment exposure.
- •The proposed modeling framework can assist clinicians to understand future trends in MM epidemiology and healthcare systems and payers to plan for future resource use allocation.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Cancer stat facts: myeloma. National Institutes of Health, National Cancer Institute, Surveillance, Epidemiology, and End Results Program.Accessed March 1, 2020)
- Drug resistance in multiple myeloma.Cancer Treat Rev. 2018; 70: 199-208
- Clinical course of patients with relapsed multiple myeloma.Mayo Clin Proc. 2004; 79: 867-874
- Management of multiple myeloma in the relapsed/refractory patient.Hematology Am Soc Hematol Educ Program. 2017; 2017: 508-517
- Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices.Expert Rev Hematol. 2016; 9: 707-717
- Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.Blood. 2014; 123: 3128-3138
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.Lancet Oncol. 2020; 21: 207-221
- BLENREP (Belantamab Mafodotin-blmf) prescribing information. GlaxoSmithKline.https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event = overview.process&ApplNo=761036Date accessed: January 14, 2021
- BLENREP 100-mg powder. Summary of product characteristics. European Medicines Agency.https://www.ema.europa.eu/en/documents/product-information/blenrep-epar-product-information_en.pdfDate accessed: April 22, 2021
- Patient population with multiple myeloma and transitions across different lines of therapy in the USA: an epidemiologic model.Pharmacoepidemiol Drug Saf. 2016; 25: 871-879
- NCCN guidelines insights: multiple myeloma, version 3.2018.J Natl Compr Canc Netw. 2018; 16: 11-20
- Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline.J Clin Oncol. 2019; 37: 1228-1263
- Recent real-world treatment patterns and outcomes in US patients with relapsed/refractory multiple myeloma.Expert Rev Hematol. 2020; 13: 1017-1025
- Multiple myeloma treatment in real-world clinical practice: results of a prospective, multinational, noninterventional study.Clin Lymphoma Myeloma Leuk. 2018; 18: e401-e419
- Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.N Engl J Med. 2007; 356: 2582-2590
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.Leukemia. 2012; 26: 149-157
Centers for Disease Control and Prevention. Death rates by 10-year age groups: United States and each state, 2007. https://www.cdc.gov/nchs/data/dvs/MortFinal2007_Worktable23r.pdf. Accessed November 11, 2020.
- Multiple myeloma: patient outcomes in real-world practice.Br J Haematol. 2016; 175: 252-264
- Daratumumab added to standard of care in patients with newly diagnosed multiple myeloma: a network meta-analysis.Eur J Haematol. 2019; 103: 542-551
- Association between autologous stem cell transplant and survival among Californians with multiple myeloma.J Natl Cancer Inst. 2019; 111: 78-85
- Treatment patterns and clinical outcomes in high-risk newly diagnosed multiple myeloma patients carrying the 17p deletion: an observational multi-center retrospective study.Am J Hematol. 2018; 93: 810-815
- Real-world outcomes of multiple myeloma: retrospective analysis of the Czech registry of monoclonal gammopathies.Clin Lymphoma Myeloma Leuk. 2018; 18: e219-e240
- Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation.Leukemia. 2018; 32: 712-718
- Rates and probabilities in economic modelling: transformation, translation and appropriate application.Pharmacoeconomics. 2007; 25: 3-6
- R: a language and environment for statistical computing, Austria: Vienna. R Core Team.Accessed February 1, 2022)
- Solving differential equations in R: package deSolve.J Stat Softw. 2010; 33: 1-25
- Long-term outcomes in patients with multiple myeloma: a retrospective analysis of the Dutch population-based haematological registry for observational studies (PHAROS).Hemasphere. 2018; 2: e45
- Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib.Ann Hematol. 2017; 96: 449-459
- Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.Leukemia. 2014; 28: 1122-1128
- Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study.Leukemia. 2017; 31: 2443-2448
- Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients.Blood Adv. 2017; 1: 455-466
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (Cassiopeia): a randomised, open-label, phase 3 study.Lancet. 2019; 394: 29-38
- Estimate of multiple myeloma patients by line of therapy in the US: population-level projections 2020-2025.Future Oncol. 2021; 17: 921-930
- FDA resources page. Food and Drug Administration.https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-isatuximab-irfc-multiple-myelomaDate accessed: January 19, 2022
- Multiple myeloma in the real world: how therapeutic landscape has changed in the last 15 years. European Hematology Association.https://library.ehaweb.org/eha/2017/22nd/181069/federica.cocito.multiple.myeloma.in.the.real.world.how.therapeutic.landscape.html(Accessed February 1, 2022)